Prognostic value of SUVmax in breast cancer and comparative analyses of molecular subtypes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prognostic value of SUVmax in breast cancer and comparative analyses of molecular subtypes

Published:2021-08-06 Issue:31 Volume:100 Page:e26745
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Lee Moon il,Jung Youn Joo,Kim Dong Il,Lee Seungju,Jung Chang Shin,Kang Seok Kyung,Pak Kyoungjune,Kim Seong Jang,Kim Hyun Yul

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference39 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Local recurrence after mastectomy or breast-conserving surgery and radiation;Freedman;Oncology (Williston Park),2000

3. Preoperative PET/CT in early-stage breast cancer;Bernsdorf;Ann Oncol,2012

4. Direct comparison of PET/CT and MRI to predict the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis;Chen;Sci Rep,2017

5. Prognostic implications of the SUVmax of primary tumors and metastatic lymph node measured by 18F-FDG PET in patients with uterine cervical cancer: a meta-analysis;Sarker;Clin Nucl Med,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative PSMA-PET parameters in localized prostate cancer: prognostic and potential predictive value;Radiation Oncology;2024-07-29

2. Baseline and early 18F-FDG PET/CT evaluations as predictors of progression-free survival in metastatic breast cancer patients treated with targeted anti-CDK therapy;Cancer Imaging;2024-07-09

3. Baseline [18F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy;European Journal of Nuclear Medicine and Molecular Imaging;2024-06-26

4. A PET‐Surrogate Signature for the Interrogation of the Metabolic Status of Breast Cancers;Advanced Science;2024-05-17

5. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial;European Journal of Nuclear Medicine and Molecular Imaging;2024-04-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3